NASDAQ:ETON Eton Pharmaceuticals Q4 2024 Earnings Results & Report $51.33 -1.55 (-2.93%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$51.50 +0.17 (+0.33%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Eton Pharmaceuticals met analyst earnings expectations and beat on revenue in its Q4 2024 results, released March 18, 2025. The company reported EPS of -$0.02 versus the -$0.02 consensus estimate, while revenue of $11.65 million topped the $10.53 million estimate by $1.12 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 18, 2025TimeBefore Market OpensConference Call10:00 AM ET Eton Pharmaceuticals EPS ResultsActual EPS-$0.02Consensus EPS -$0.02Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersEton Pharmaceuticals Revenue ResultsActual Revenue$11.65 millionExpected Revenue$10.53 millionBeat/MissBeat by +$1.12 millionYoY Revenue GrowthN/AUpcoming EarningsEton Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Eton Pharmaceuticals Q4 2024 Earnings FAQ Did Eton Pharmaceuticals beat earnings estimates for Q4 2024? Eton Pharmaceuticals (NASDAQ:ETON) reported earnings of -$0.02 per share for Q4 2024, matching the consensus estimate of -$0.02. The report was announced on Tuesday, March 18, 2025. What was Eton Pharmaceuticals' revenue for Q4 2024? Eton Pharmaceuticals reported revenue of $11.65 million for Q4 2024, against a consensus estimate of $10.53 million. When is Eton Pharmaceuticals' next earnings date? Eton Pharmaceuticals' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Eton Pharmaceuticals on the company's earnings history page. Eton Pharmaceuticals Earnings HeadlinesHC Wainwright Reaffirms "Buy" Rating for Eton Pharmaceuticals (NASDAQ:ETON)October 16 at 1:55 AM | americanbankingnews.comEton Pharmaceuticals, Inc. and Aquestive Therapeutics, Inc. Announce Exclusive U.S. Licensing Agreement for Libervant® Buccal FilmOctober 14 at 2:44 PM | marketscreener.comMDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 16 at 1:00 AM | Profits Run (Ad)Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmOctober 14 at 6:50 AM | globenewswire.comEton Pharmaceuticals (NASDAQ:ETON) Stock: Insider David Krempa Sells 4,166 SharesOctober 8, 2026 | americanbankingnews.comEton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO(R) (miltefosine) CapsulesSeptember 29, 2026 | marketscreener.comMSee More Eton Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email. Email Address About Eton PharmaceuticalsEton Pharmaceuticals (NASDAQ:ETON) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs. Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions. Its products are primarily marketed through the U.S. healthcare system. Founded in 2017 and headquartered in Deer Park, Illinois, Eton has built its business through internal product development, licensing arrangements, and acquisitions of pharmaceutical assets. Sean Brynjelsen, the company’s founder, serves as president and chief executive officer.View Eton Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure3 Stocks to Watch as Wall Street Wealth Fuels Consumer SpendingASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could Deepen Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
